GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Cyclically Adjusted PB Ratio

Pharmicell Co (XKRX:005690) Cyclically Adjusted PB Ratio : 4.19 (As of Jun. 10, 2024)


View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Cyclically Adjusted PB Ratio?

As of today (2024-06-10), Pharmicell Co's current share price is ₩5980.00. Pharmicell Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ₩1,426.19. Pharmicell Co's Cyclically Adjusted PB Ratio for today is 4.19.

The historical rank and industry rank for Pharmicell Co's Cyclically Adjusted PB Ratio or its related term are showing as below:

XKRX:005690' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.42   Med: 6.84   Max: 15.93
Current: 4.19

During the past years, Pharmicell Co's highest Cyclically Adjusted PB Ratio was 15.93. The lowest was 2.42. And the median was 6.84.

XKRX:005690's Cyclically Adjusted PB Ratio is ranked worse than
75.49% of 661 companies
in the Biotechnology industry
Industry Median: 1.67 vs XKRX:005690: 4.19

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Pharmicell Co's adjusted book value per share data for the three months ended in Mar. 2024 was ₩1,317.650. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₩1,426.19 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharmicell Co Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Pharmicell Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Cyclically Adjusted PB Ratio Chart

Pharmicell Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.58 11.07 8.40 7.35 4.18

Pharmicell Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.01 5.00 4.89 4.18 4.38

Competitive Comparison of Pharmicell Co's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Pharmicell Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmicell Co's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmicell Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pharmicell Co's Cyclically Adjusted PB Ratio falls into.



Pharmicell Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pharmicell Co's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=5980.00/1426.19
=4.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmicell Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Pharmicell Co's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1317.65/118.8477*118.8477
=1,317.650

Current CPI (Mar. 2024) = 118.8477.

Pharmicell Co Quarterly Data

Book Value per Share CPI Adj_Book
201406 1,867.899 99.353 2,234.412
201409 1,865.949 99.608 2,226.365
201412 1,584.210 99.098 1,899.935
201503 1,583.128 99.720 1,886.794
201506 1,622.941 100.050 1,927.864
201509 1,610.914 100.110 1,912.431
201512 1,596.350 100.220 1,893.061
201603 1,595.170 100.560 1,885.265
201606 1,581.893 100.790 1,865.308
201609 1,634.231 101.460 1,914.297
201612 1,620.619 101.560 1,896.483
201703 1,600.317 102.850 1,849.237
201706 1,573.576 102.610 1,822.589
201709 1,564.061 103.490 1,796.164
201712 927.002 102.990 1,069.735
201803 956.080 104.100 1,091.527
201806 1,024.773 104.130 1,169.614
201809 1,025.317 105.650 1,153.399
201812 792.214 104.350 902.279
201903 808.318 104.490 919.387
201906 827.142 104.880 937.299
201909 825.431 105.200 932.515
201912 859.426 105.120 971.659
202003 873.716 105.540 983.884
202006 923.367 104.870 1,046.439
202009 935.423 106.200 1,046.826
202012 952.611 105.765 1,070.441
202103 984.207 107.357 1,089.547
202106 1,020.467 107.579 1,127.363
202109 1,080.112 108.759 1,180.303
202112 1,065.482 109.676 1,154.579
202203 1,245.909 111.806 1,324.380
202206 1,311.041 114.083 1,365.799
202209 1,375.833 114.831 1,423.955
202212 1,277.663 115.200 1,318.117
202303 1,340.685 116.550 1,367.120
202306 1,349.836 117.140 1,369.515
202309 1,367.416 119.111 1,364.391
202312 1,339.860 118.848 1,339.860
202403 1,317.650 118.848 1,317.650

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pharmicell Co  (XKRX:005690) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pharmicell Co Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmicell Co (XKRX:005690) Business Description

Traded in Other Exchanges
N/A
Address
12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co (XKRX:005690) Headlines

No Headlines